Phase I/II First-In-Human open-label trial to assess safety and efficacy of STX-241 in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) resistant to EGFR tyrosine kinase inhibitors (TKIs).
Principal Investigator
Dr. G. Ruiter
Drugs
STX-241 (a mutant selective Central Nervous System (CNS)-penetrant fourth generation EGFR TKI)
This study examines the tolerance and activity of STX-241 in patients with non-small cell lung cancer, who no longer respond to standard treatment with EGFR tyrosine kinase inhibitors.
Read more on clinicaltrials.gov